Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China

PURPOSE: Agents that inhibit sodium glucose co-transporter 2 (SGLT2), including canagliflozin and dapagliflozin, become available for the treatment of Chinese patients with type 2 diabetes mellitus (T2DM). This study assessed the economic outcomes of canagliflozin 100 mg versus dapagliflozin 10 mg i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Xingyun, Wan, Xu, Wu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521739/
https://www.ncbi.nlm.nih.gov/pubmed/31143117
http://dx.doi.org/10.3389/fphar.2019.00480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521739/
https://www.ncbi.nlm.nih.gov/pubmed/31143117
http://dx.doi.org/10.3389/fphar.2019.00480

Ejemplares similares